Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements (Tables)

v3.19.1
Collaboration and License Agreements (Tables)
12 Months Ended
Dec. 31, 2018
Collaboration And License Agreements [Abstract]  
Summary of Recognized Revenue

The Company has recognized revenue from its collaboration and license agreements as follows:

 

 

 

Year Ended December 31,

 

 

 

2018

 

 

2017

 

 

2016

 

 

 

(in thousands)

 

Collaboration revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Celgene Corporation (“Celgene”) (1)

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of up-front payment

 

$

6,567

 

 

$

16,694

 

 

$

27,730

 

Research and development services

 

 

119

 

 

 

660

 

 

 

-

 

Milestones and contingent payments

 

 

10,000

 

 

 

27,252

 

 

 

26,271

 

Total

 

 

16,686

 

 

 

44,606

 

 

 

54,001

 

Merck Sharp & Dohme Corporation (“Merck”)—

   related party:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of up-front payment

 

 

6,985

 

 

 

-

 

 

 

 

 

Research and development services

 

 

1,541

 

 

 

-

 

 

 

 

 

Total

 

 

8,526

 

 

 

-

 

 

 

-

 

Merck KGaA, Darmstadt, Germany (operating in

   the United States and Canada under the name

   “EMD Serono”):

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of up-front payment

 

 

4,142

 

 

 

4,120

 

 

 

4,120

 

Research and development services

 

 

3,033

 

 

 

3,015

 

 

 

1,610

 

Total

 

 

7,175

 

 

 

7,135

 

 

 

5,730

 

Total collaboration revenue

 

$

32,387

 

 

$

51,741

 

 

$

59,731

 

Other revenue

 

 

 

 

 

 

 

 

 

 

 

 

Celgene Corporation (1):

 

 

 

 

 

 

 

 

 

 

 

 

Development and manufacturing services and

   clinical product supply

 

$

4,501

 

 

$

-

 

 

 

 

 

SutroVax—related party:

 

 

 

 

 

 

 

 

 

 

 

 

Supply and other

 

 

1,531

 

 

 

-

 

 

 

 

 

Total other revenue

 

$

6,032

 

 

$

-

 

 

$

-

 

Total revenue

 

$

38,419

 

 

$

51,741

 

 

$

59,731

 

 

(1)

Includes $5.0 million of collaboration revenue and $3.9 million of other revenue from Celgene as related party revenue. Celgene was a related party through September 30, 2018 as it held more than 10% of our common stock for the periods presented until the closing of our IPO.